MorphoSys AG Unsponsored ADR (NYSE:MOR) Expected to Announce Quarterly Sales of $12.43 Million
Equities research analysts expect that MorphoSys AG Unsponsored ADR (NYSE:MOR) will announce $12.43 million in sales for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for MorphoSys’ earnings, with the highest sales estimate coming in at $12.65 million and the lowest estimate coming in at $12.21 million. MorphoSys posted sales of $11.98 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 3.8%. The company is scheduled to issue its next earnings results on Wednesday, March 11th.
On average, analysts expect that MorphoSys will report full-year sales of $79.42 million for the current year, with estimates ranging from $78.81 million to $80.03 million. For the next year, analysts anticipate that the business will post sales of $115.13 million, with estimates ranging from $88.80 million to $164.24 million. Zacks’ sales averages are an average based on a survey of research firms that cover MorphoSys.
MorphoSys (NYSE:MOR) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.27) by $0.22. The business had revenue of $38.95 million for the quarter, compared to analyst estimates of $10.58 million.
MorphoSys Company Profile
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnership with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 drugs for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
Recommended Story: What are the Benefits of Index Funds?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.